Researchers at the University of British Columbia have identified a previously unrecognized inherited form of prostate cancer linked to the CDK12 gene. Although this genetic variant is extremely rare, it is associated with aggressive disease that often spreads beyond the prostate at a relatively young age. The finding offers a new target for genetic screening that could help doctors detect cancer in high-risk families before it becomes untreatable.
Most prostate cancers develop as genetic changes accumulate in cells over many years. However, a small percentage of cases stem from mutations passed down from parents. While mutations in BRCA1 and BRCA2 are well-known drivers of hereditary breast, ovarian, and prostate cancers, this new study points to CDK12 as another significant marker. The research, published in Cancer Discovery, examined genetic data from more than 4,500 individuals with aggressive prostate cancer.
Early Metastasis in CDK12 Carriers
The team identified five unrelated men who carried inherited mutations in the CDK12 gene. Every single one of these patients had developed metastatic prostate cancer by the time of their diagnosis. The ages of these men ranged from 44 to 62, indicating that the inherited mutation accelerates the progression of the disease significantly compared to sporadic cases.
“What’s striking is that every patient we identified with this inherited mutation had already developed metastatic disease by the time they were diagnosed,” said Dr. Alexander Wyatt, senior author of the study and associate professor of urologic sciences at UBC. “The opportunity now is to identify these families earlier and give people the chance to benefit from enhanced screening, when there are still curative treatment options.”
The discovery challenges a long-held scientific assumption. Researchers previously believed that harmful changes in CDK12 occurred spontaneously within cancer cells rather than being inherited from a parent. To confirm the hereditary nature of the mutations, the team analyzed the patients’ tumors for a specific pattern of genetic damage. This molecular fingerprint confirmed that the loss of CDK12 function was directly driving the development of the cancers.
Expanding Genetic Testing Panels
Inherited CDK12 mutations appear in approximately one out of every 1,000 people with aggressive prostate cancer. While this frequency is low, the researchers estimate that hundreds of families worldwide could be affected. The study involved an international collaboration including institutions in Australia, the Netherlands, Spain, Belgium, and the University of Washington.
Dr. Sofie Tolmeijer, lead author and a postdoctoral fellow in the Wyatt lab, noted that the tumors provided a clear genetic signature pointing back to CDK12. She emphasized that finding one person with the mutation allows doctors to test other family members. “Finding one person with an inherited mutation gives us the opportunity to identify other family members at risk and help them take action before cancer develops or spreads,” Tolmeijer said.
One of the most practical aspects of this discovery is that it does not require new technology to implement. The researchers recommend adding CDK12 to standard genetic testing panels used to assess hereditary cancer risk. These panels already examine multiple genes associated with inherited susceptibility. Because the clinical tools to detect CDK12 mutations exist, integrating this gene into routine care could happen quickly.
“One of the most exciting aspects of this discovery is that we already have the technology needed to act on it,” Wyatt said. “Adding CDK12 to existing genetic tests is relatively straightforward, which means this discovery could move from the research lab into clinical care much more quickly.”
The study also raised questions about the gene’s role in other cancers. Several men with inherited CDK12 mutations had relatives with a history of ovarian cancer. The investigators also identified a woman with ovarian cancer who carried the same inherited mutation. Her tumor displayed the same genetic signature seen in the prostate cancer cases. While more research is needed to confirm a link, these observations suggest CDK12 may influence hereditary cancer risk beyond the prostate.
For families carrying these rare mutations, early identification could be life-saving. Enhanced screening programs may allow for closer medical monitoring and earlier intervention. “With the right genetic testing and screening programs, we envision a future where no one who inherits one of these mutations dies from cancer,” Wyatt said.
Source: ScienceDaily

